New Insights Into the Treatment of Multiple Myeloma With Histone Deacetylase Inhibitors

Current Pharmaceutical Design - United Arab Emirates
doi 10.2174/13816128130412
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bentham Science Publishers Ltd.

Related search

Histone Deacetylase Inhibitors in Multiple Myeloma

Hematology Reports
Hematology
2009English

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat

Pharmacotherapy
Pharmacology
2015English

Inhibitors of Histone-Deacetylase

Journal of Applied Biomedicine
GeneticsMolecular BiologyPharmacologyBiochemistryBiological SciencesToxicologyMedicineAgriculturalNeurosciencePharmaceutics
2005English

Gene Expression-Based Prediction of Myeloma Cell Sensitivity to Histone Deacetylase Inhibitors

British Journal of Cancer
Cancer ResearchOncology
2013English

The Short-Term Effect of Histone Deacetylase�inhibitors, Chidamide and Valproic Acid, On�the�NF‑κB�pathway in Multiple Myeloma Cells

International Journal of Molecular Medicine
MedicineGenetics
2018English

Pharmacogenomics and Histone Deacetylase Inhibitors

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2016English

Manipulation of B-Cell Responses With Histone Deacetylase Inhibitors

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2015English

Histone Deacetylase Inhibitors From Burkholderia Thailandensis

Journal of Natural Products
Organic ChemistryMolecular MedicinePharmacologyComplementaryPharmaceutical ScienceAnalytical ChemistryAlternative MedicineDrug Discovery
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy